Bioiberica authorized to sell mobility ingredient in Australia and New Zealand
21 Mar 2018 --- Bioiberica has obtained authorization to sell its Mobilee product in Australia and New Zealand as a medicinal supplement and non-traditional ingredient for use in functional foods. The Therapeutic Goods Administration and Food Standard Australia New Zealand found that this patented natural ingredient rich in hyaluronic acid, collagen and polysaccharides can be included in medicinal supplements and food for daily consumption.
“This approval is key to Bioiberica’s international expansion plan in the joint health and mobility area This year the company plans to sign different licensing and distribution agreements with local companies across the two countries,” says Jaume Reguant, Director of the Bioiberica International Human Health division.
Nearly seven million Australians have mobility problems, of which more than two million suffer from osteoarthritis. Speaking earlier with NutritionInsight, Jose Antonio López Sánchez, Product Manager Human Health at Bioiberica, noted that there is a growing market for products that not just address joint health but also cater to a wider concept of mobility, which includes bone and muscle health.
According to Innova Market Insights, product launches targeting mobility grew 37 percent between 2012 and 2016, he notes.
The product's efficacy and safety have been tested in six preclinical studies and five randomized clinical studies over five years: “Mobilee is an innovative product with health benefits, which the human body absorbs naturally. Its benefits extend beyond the advantages afforded by hyaluronic acid. Taking Mobilee every day for at least two months helps maintain joint health and muscle function,” said Dr. Martínez, Head of Development at Bioiberica.
Mobilee has also been approved by the European Commission as a Novel Food and has GRAS (Generally Recognized as Safe) status in the US.
Bioiberica is a global company specializing in the research, production and sale of biomolecules such as chondroitin sulfate, glucosamine, heparin and hyaluronic acid.
To contact our editorial team please email us at editorial@cnsmedia.com
Subscribe now to receive the latest news directly into your inbox.
COMPANY DETAILS
Av. Països Catalans 34, planta 2ª, Esplugues de Llobregat
Barcelona
08950
Spain
www.bioiberica.com
healthcare@bioiberica.com
Tel: 0034 93 4904908
Fax: 0034 93 4909711HEALTH CATEGORIES
Bioiberica is a global Life Science company committed to improving the health and wellbeing of people, animal and plants, worldwide. With over 45 years of experience, we are experts at identifying, extracting and developing molecules of high biological and therapeutic value, which are transformed into high-quality products for the pharmaceutical, nutraceutical, veterinary and agricultural industries.
Collavant n2 - a trusted source of high quality native (undenatured) type II collagen for joint health innovation, endorsed by multiple scientific studies.
Mobilee® - a hyaluronic acid matrix ingredient containing a patented combination of hyaluronic acid, polysaccharides and collagen that act synergistically to support joint and muscle health.
Dermial® - a hyaluronic acid matrix ingredient containing a high concentration of hyaluronic acid, glycosaminoglycans and collagen that helps keep the skin nourished and hydrated through its anti-aging and regenerative properties.
DAOgest - a high quality ingredient containing diamine oxidase (DAO) enzyme for dietary supplements that support histamine digestion.
Tendaxion - a specific formula containing hydrolysed type I collagen and mucopolysaccharides for supporting tendon health.
